This study investigated the inhibitory effect and mechanism of curcumol on growth human hepatocellular carcinoma (HCC) HepG2 xenografts in nude mice. Curcumol was isolated from zedoary turmeric oil. The xenograft model mice established. Forty modeled were divided into model, cisplatin, cisplatin+curcumol groups. latter three groups treated with 2 mg/kg 100 cisplatin combined curcumol, respectiv...

Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors developed a prognostic instrument help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 with who treated via cisplatin. These included age, sex, Karnofsky performance ...

Cisplatin is the first l ine chemotherapy for the treatment of several cancers. However, the development of cisplatin resistance represents a major clinical problem and the mechanisms of acquired resistance are not fully understood. Here we show that degradation of the BH3only pro-apoptotic protein Bim plays an important role in cisplatin resistance in ovarian cancer. Specifically, we show that...

BACKGROUND Cisplatin-based therapy is a pivotal type of chemotherapy for non-small cell lung cancer (NSCLC) and chemoresistance to cisplatin represents one of the most significant barriers to improving long-term clinical outcomes. MATERIALS AND METHODS The present study aimed at examining metallothionein (MT) expression in six NSCLC cell lines as well as examining effects of exposure to cispl...

To ascertain whether resistance to cis-diamminedichloroplatinum(II) (cisplatin) could be overcome, we determined the effects of amphotericin B (AmB), an antifungal agent, on cisplatin cytotoxicity, cisplatin-induced DNA interstrand cross-links formation, and cellular accumulation of cis platin in human lung cancer cell lines, PC-9, PC-14, PC-7, and H69 and their corresponding respective cisplat...

Cisplatin, a commonly used cancer chemotherapeutic, has a dose-limiting side effect of nephrotoxicity. Approximately 30% of patients administered cisplatin suffer from kidney injury, and there are limited treatment options for the treatment of cisplatin-induced kidney injury. Suramin, which is Federal Drug Administration-approved for the treatment of trypanosomiasis, improves kidney function af...

Cisplatin is one of the most commonly used therapeutic drugs for cancer therapy, yet prolonged cisplatin treatment frequently results in drug resistance. To enhance therapeutic effect of cisplatin, we conducted a high throughput screening using a kinase library containing 704 kinases against triple negative breast cancer (TNBC) cells. We demonstrated that cisplatin activates ATR, CHK1 and WEE1,...

Resistance to cisplatin is a major problem in the treatment of solid tumors. To investigate the determinants of cisplatin resistance, we have identified cisplatin-inducible genes by differential display of mRNA. One of the cisplatin-inducible genes was identified as activating transcription factor 4 (ATF4). Northern blot analysis demonstrated that expression of ATF4 is inducible at the transcri...

Resistance to cisplatin is a major problem in the treatment of solid tumors. To investigate the determinants of cisplatin resistance, we have identified cisplatin-inducible genes by differential display of mRNA. One of the cisplatin-inducible genes was identified as activating transcription factor 4 (ATF4). Northern blot analysis demonstrated that expression of ATF4 is inducible at the transcri...

BACKGROUND Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) is associated with poor survival. Platinum-based chemotherapy is often a first-line treatment. Pemetrexed has shown single-agent activity in SCCHN and in combination with cisplatin for other tumors. This trial examined the efficacy of pemetrexed-cisplatin for SCCHN. METHODS In a double-blind phase 3 trial,...